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MaOrthostatic hypotension (OH) is a common cardiovascular disorder, with or without signs of underlying neurodegener-
ative disease. OH is diagnosed on the basis of an orthostatic challenge and implies a persistent systolic/diastolic blood
pressure decrease of at least 20/10 mm Hg upon standing. Its prevalence is age dependent, ranging from 5% in
patients <50 years of age to 30% in those >70 years of age. OH may complicate treatment of hypertension, heart failure,
and coronary heart disease; cause disabling symptoms, faints, and traumatic injuries; and substantially reduce quality of
life. Despite being largely asymptomatic or with minimal symptoms, the presence of OH independently increases mor-
tality and the incidence of myocardial infarction, stroke, heart failure, and atrial ﬁbrillation. In this review, we outline the
etiology and prevalence of OH in the general population, summarize its relationship with morbidity and mortality, pro-
pose a diagnostic and therapeutic algorithm, and delineate current challenges and future perspectives.
(J Am Coll Cardiol 2015;66:848–60) © 2015 by the American College of Cardiology Foundation.O rthostatic hypotension (OH) is a keymanifestation of autonomic dysfunction,typically observed when cardiovascular
adaptive mechanisms fail to compensate for the
reduction in venous return that normally occurs on
assuming the upright position. It reﬂects a structural
or functional sympathetic denervation or a deranged
reﬂex regulation of sympathetic outﬂow (1). OH is
the second most common etiology of syncope, occur-
ring in approximately 15% of syncope presentations
(2). It frequently affects older people and patients
who have neurodegenerative disease, diabetes, or hy-
pertension. Unfortunately, OH is often unrecognized
or misdiagnosed and may be an overlooked factor
associated with increased cardiovascular morbidity
and all-cause mortality. Its management includes
both pharmacological and nonpharmacological mea-
sures that are not always satisfactory and may lead
to complications (3). In this review, we ﬁrst outline
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THE HOMEOSTATIC REGULATION
OF BLOOD PRESSURE
Cardiovascular blood pressure (BP) homeostasis re-
fers to compensatory adjustments aimed at buffering
changes in BP and opposing cardiovascular remodel-
ing. Regulation of BP is a very complex physiological
function that depends on a continuum of actions of
the cardiovascular, neural, renal, and endocrine sys-
tems (4). In contrast to the local (peripheral) regula-
tion of tissue BP, which primarily aims to achieve a
tight matching of regional blood ﬂow to local meta-
bolic demands and occurs through locally produced
mediators (autacoids), including eicosanoids, nitric
oxide, endothelins, and tissue plasminogen activator,
the central circulation maintains tight control of BP
through changes in cardiac output and vascular tone.f Excellence on Aging, Chieti, Italy; yDepartment of
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AB BR E V I A T I O N S
AND ACRONYM S
BP = blood pressure
ECG = electrocardiogram
HIP = hydrostatic indifference
point
HUT = head-up tilt test
OH = orthostatic hypotension
SBP = systolic blood pressure
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849Such changes are mediated by the autonomic nervous
system. The sympathetic and parasympathetic com-
ponents of the autonomic nervous system play a
crucial role in the ﬁne-tuning of BP, enabling the
body to respond to physiological stressors. The sym-
pathetic nervous system plays the predominant role
in determining the level of arterial BP and the dis-
tribution of cardiac output. Despite the existence of
cholinergic vasodilation in some vascular beds, the
overall contribution of the parasympathetic nervous
system to the regulation of vascular tone is almost
negligible, in contrast to the role of the para-
sympathetic nervous system in the regulation of
cardiac functions via its negative chronotropic and
inotropic effects.
Central regulatory mechanisms control the sym-
pathetic outﬂow to the cardiovascular system in both
the short and long term (5). Short-term reﬂex control
of the sympathetic vasomotor activity is regulated by
homeostatic feedback mechanisms, such as the
baroreceptor and chemoreceptor reﬂexes. Central
mechanisms also produce speciﬁc patterns of sym-
pathetic activity according to different external
stimuli or stresses (6,7). In the long term, cardiovas-
cular homeostasis depends on a more complex
interplay of several mechanisms, including changes
in the sympathetic vasomotor outﬂow, renal control
of extracellular volume, pressure natriuresis, and
the activity of antagonistic “push-pull” systems (8),
such as the kallikrein-kinin and renin-angiotensin-
aldosterone systems (5,6,9–12).
PHYSIOLOGY OF UPRIGHT POSTURE. Orthostatic
stress is a common daily challenge for humans when
posture changes from lying to standing or during pro-
longed quiet standing. Almost immediately, with the
transition from the supine (recumbent) to the upright
(erect) position, a gravitational shift of nearly 500ml of
blood away from the chest to the distensible venous
capacitance system below the diaphragm (venous
pooling) occurs. This results in a rapid decrease in
central blood volume and a subsequent reduction of
ventricular preload, stroke volume, and mean BP (13).
In the vascular system, a reference quantitative
determinant of these changes is the venous hydro-
static indifference point (HIP), when pressure is inde-
pendent of posture (14). In humans, the venous HIP is
approximately at the diaphragmatic level, whereas the
arterial HIP lies close to the level of the left ventricle
(14). The venous HIP is dynamic and is signiﬁcantly
affected by venous compliance and muscular activity.
Upon standing, contractions of lower limb mus-
cles, along with the presence of venous valves, pro-
vide an intermittent unidirectional ﬂow, moving the
venous HIP toward the right atrium (15). Respirationmay also increase venous return because
deep inspiration results in both a decline in
thoracic pressure and an increase in intra-
abdominal pressure, which lowers retro-
grade ﬂow due to compression of both the
iliac and femoral veins (14). To provide an
appropriate perfusion pressure to critical or-
gans, an effective set of the neural regulatory
system is promptly activated upon standing
(6). The sympathetic nervous system is fast
acting and primarily modulated by mechanoreceptors
and, to a smaller degree, by chemoreceptors. Arterial
baroreceptors (high-pressure receptors) are located in
the carotid sinus and the aortic arch and—by
conveying baroceptive impulses via carotid sinus and
aortic depressor nerves to the brainstem, notably in
the nucleus of the solitary tract—determine tonic in-
hibition of vasomotor centers (16) (Figure 1). In
contrast, cardiopulmonary baroreceptors (volume
receptors) are located in the great veins and the car-
diac chambers and detect changes in the ﬁlling of the
central venous circulation but are not essential for
orthostatic cardiovascular homeostasis (16). A sudden
drop in BP in the carotid sinus and the aortic arch
triggers baroreceptor-mediated compensatory mech-
anisms within seconds, resulting in increased heart
rate, myocardial contractility, and peripheral vaso-
constriction (17). An additional local axon reﬂex, the
veno-arteriolar axon reﬂex, results in constriction of
arterial ﬂow to the muscles, skin, and adipose tissue,
leading to almost one-half of the increase in vascular
resistance in the limbs upon standing (14,18,19).
Ultimately, orthostatic stabilization is normally ach-
ieved in roughly 1 min or less. During prolonged quiet
standing, in addition to venous pooling, trans-
capillary ﬁltration in the subdiaphragmatic space
further reduces both central blood volume and car-
diac output by approximately 15% to 20% (20,21).
This transcapillary shift equilibrates after approxi-
mately 30 min of upright posture, which can result in
a net fall in plasma volume of up to 10% over this
time. Continued upright posture also results in acti-
vation of neuroendocrine mechanisms, such as the
renin-angiotensin-aldosterone system, which may
vary in intensity depending on the volume status of
the patient (18). Still, the most important homeostatic
response to prolonged orthostatic stress appears to
be the carotid baroreﬂex-mediated increase of pe-
ripheral vascular resistance. The inability of any one
of these factors to perform adequately or coordi-
nately may result in a failure of the system to
compensate for an initial or sustained postural chal-
lenge. This may produce a transient or persistent
state of hypotension, which, in turn, can lead to
FIGURE 1 Baroreceptor-Mediated Regulation of Blood Pressure
The afferent pathway transfers information from arterial baroreceptors in the carotid
artery and the aortic arch. This information reaches the vasomotor center in the medulla
oblongata. The efferent pathway regulates 2 basic cardiovascular responses: heart rate and
vascular tone. The hypothalamus can then activate vasopressin release as additional
regulatory mechanisms. Higher brain functions can modulate automatic cardiovascular
responses.
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850symptomatic cerebral hypoperfusion and loss of
consciousness, either in the early or late phase of
orthostatic challenge (3).
ORTHOSTATIC INTOLERANCE SYNDROMES: DEFINITIONS,
ETIOLOGIES, AND TYPICAL FORMS. Orthostatic intol-
erance deﬁnes the inability to tolerate the upright
posture as a consequence of varying degrees of
autonomic nervous system dysfunction (22). A num-
ber of different disorders of orthostatic control have
been identiﬁed that are unique in many ways,
although they share certain characteristics (14). Ac-
cording to the 2011 updated consensus statement
endorsed by major international autonomic nervous
system and neurological societies and in agreement
with the European Society of Cardiology, orthostatic
intolerance syndromes can be classiﬁed into at least 3
categories: 1) orthostatic hypotension; 2) neutrallymediated (reﬂex) syncope; and 3) postural tachy-
cardia syndrome (23,24). Both reﬂex syncope and
postural orthostatic tachycardia syndrome have been
discussed in detail elsewhere (22,25–27).
OH can be classiﬁed as either primary or secondary
(1) and can be further subdivided into acute and
chronic forms (18) (Figure 2). On a pathophysiological
basis, OH may be divided into 2 broad categories
dealing with structural (neurogenic) or functional (or
non-neurogenic) causes of autonomic nervous system
failure. Neurogenic OH is a key manifestation of
chronic autonomic failure in primary neurodegener-
ative disorders, such as pure autonomic failure,
multiple system atrophy, or Parkinson disease, but
can also be secondary to neurological diatheses
associated with diabetes, amyloidosis, or advanced
renal failure (3). Factors that may cause functional
impairment of the autonomic nervous system include
treatment with vasodilators, tricyclic antidepres-
sants, diuretics, or chemotherapeutic agents; abso-
lute or relative reduction in circulating blood volume;
venous pooling; and inotropic and/or chronotropic
heart failure (28,29).
OH may provoke signs and symptoms of cerebral
hypoperfusion, including nausea, fatigue, light-
headedness, dizziness, “coat-hanger” pain, visual
blurring, and eventually syncope. Whether or not the
patient experiences symptoms is as much dependent
on the rate of the decrease in pressure as it is upon the
absolute degree of change. Most patients with OH are
asymptomatic or have few nonspeciﬁc symptoms,
thus accounting for the high rate of unrecognized
cases. Patients with OH may also suffer from supine
hypertension, as well as wide swings in BP, or
may experience abnormal responses to a number of
pharmacological or physiological challenges (14,18).
Symptoms are more common and more severe in the
morning and after waking and are typically exacer-
bated by conditions predisposing to peripheral
venous pooling and dehydration, such as heat,
fever, alcohol drinking, urination, post-exercise time,
and immobilization. Also, patients with autonomic
failure are more susceptible to post-prandial hypo-
tension, especially when consuming large meals and
carbohydrate-rich food, due to gastric distension,
release of vasodilatory peptides, and splanchnic blood
pooling (30). Interestingly, a common complaint is
nocturnal polyuria, which is the result of redistribu-
tion of peripheral blood to central areas while in the
recumbent position and is further exacerbated by
forced natriuresis with concomitant supine hyper-
tension. Hence, these patients may suffer signiﬁcant
intravascular volume loss overnight, enhancing the
tendency toward morning hypotension.
FIGURE 2 Etiology of Primary and Secondary Chronic Autonomic Failure With Symptoms of Orthostatic Hypotension
Chronic autonomic failure
(orthostatic hypotension)
Primary
Parkinson disease
Multiple system atrophy
Pure autonomic failure
Lewy body dementia
Autoimmune autonomic gangliopathy
Rare hereditary disorders
(familial dysautonomia, dopamine beta-hydrolase
deficiency)
Idiopathic (etiology unknown)
Secondary
Iatrogenic (drug-related)
Diabetes mellitus
Cardiovascular diseases
(sick-sinus syndrome, AV-block, heart failure, aortic stenosis,
pulmonary hypertension, essential hypertension)
Renal failure
Autoimmune diseases
Volume depletion
Venous pooling
Alcoholic polyneuropathy
Endocrine disorders
(adrenal insufficiency, thyroid diseases, diabetes insipidus)
Amyloidosis
Multiple myeloma
Paraneoplastic syndromes
Cerebrovascular disease
Multiple sclerosis
Spinal cord diseases
Orthostatic hypotension caused by primary disease of the autonomic nervous system (left panel) is often referred to as neurogenic orthostatic
hypotension. AV ¼ atrioventricular.
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851On the basis of temporal changes in orthostatic BP,
3 different clinical variants of OH have been pro-
posed: classic, delayed, and initial OH.
Class i c OH. Classic OH (Figure 3A) is deﬁned as a
sustained reduction in systolic BP (SBP) of at least
20 mm Hg and/or diastolic BP of at least 10 mm Hg,
within 30 to 180 s of active standing or during a head-
up tilt test of at least 60 (24). In patients with supine
hypertension, a reduction in systolic BP of at least 30
mm Hg is considered to be a more appropriate crite-
rion for OH because the magnitude of the BP decrease
is proportional to baseline values (24). Although
closely related to neurogenic OH, classic OH rarely
features symptoms of generalized autonomic failure
(1,3,28), and after extensive neurological evaluation,
approximately one-third of patients have no identi-
ﬁable etiology (29).
In many cases when the structural autonomic dis-
ease cannot be conﬁrmed, the term idiopathic OH
has been widely used (29). Recent data indicate that
autoimmune activity against adrenergic and musca-
rinic receptors may be responsible for exaggerated
vasodilation and symptoms of OH in the idiopathic
form, but further studies are needed (31). It should beemphasized that the diagnostic rate of neurogenic
OH may differ between specialized neurological
centers and cardiology-focused syncope units, with
higher rates of neurodegenerative disorders expected
in the former. Nonetheless, classic OH constitutes
a key and typical manifestation of sympathetic
neurocirculatory failure (32), causing impaired
chronotropic and vascular responses during early
orthostasis.
Delayed OH. Delayed OH (Figure 3B) is due to
gradual impairment of adaptive mechanisms during
orthostasis, resulting in a slow progressive drop in
arterial pressure (BP decrease $20/10 mm Hg or $30/
15 mm Hg in patients with hypertension) between
3 and 45 min. It has been associated with milder ab-
normalities of sympathetic adrenergic function, sug-
gesting that this disorder may be a less severe or an
early form of autonomic failure, along with age-
related impairment of compensatory reﬂexes and
with a stiffer, more pre-load–dependent heart in older
patients (23,33). The absence of bradycardia or pauses
usually differentiates delayed OH from reﬂex syn-
cope, although mixed forms are often encountered in
clinical practice.
FIGURE 3 Tracings During a Head-Up Tilt Test Performed in 2 Prototypical Patients With Unexplained Transient Loss of Consciousness
The upper tracing in each panel shows a beat-to-beat blood pressure (BP) measurement and consecutive test stages. The lower tracing shows the heart rate. Red arrows
mark the moment when syncope occurs. (A) A 52-year-old woman with classic orthostatic hypotension and reﬂex syncope during passive head-up tilt (HUT).
(B) A 74-year-old woman with delayed orthostatic hypotension and syncope during passive HUT.
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853In i t ia l OH. In contrast to the classic and delayed
forms, initial OH is deﬁned as a transient BP decrease
(SBP decrease >40 mm Hg and/or diastolic BP
decrease >20 mm Hg) within 30 s of standing (3). This
may be an unrecognized cause of syncope (34) and is
related to an exaggerated and immediate transient
decrease in arterial BP upon standing. It is exclusively
associated with active standing, whereas the drop in
BP during passive tilting is signiﬁcantly smaller, or, in
many cases, totally absent. The mechanism of initial
OH involves a short-lasting mismatch between a
sudden decrease in venous return and neurally
mediated compensatory vasoconstriction. The diag-
nosis of initial OH is quite challenging and can only be
conﬁrmed by an active standing test with continuous
BP monitoring.
EPIDEMIOLOGICAL AND PROGNOSTIC ASPECTS OF OH.
OH has been traditionally associated with neuro-
degenerative diseases (1), frailty in elderly patients
(35), and chronic heart failure (36), but it is also
a frequent ﬁnding among patients with hypertension
(37,38) and patients with diabetes (39). In published
reports, its prevalence ranges between 6% and 35% or
more, depending on age and associated comorbid-
ities, showing a strong association with elevated BP
(37,38,40,41). In many chronic conditions, such as
renal failure or autoimmune diseases, OH has a higher
prevalence than in the general population, suggesting
the multifactorial etiology of autonomic failure.
There is now growing evidence that disorders of
postural hemodynamic control predict all-cause
mortality (42–44) and incidence of cardiovascular
disease (44,45), being prognostically more relevant
than the ambulatory BP monitoring–derived night-
time reverse dipping (46). According to the available
longitudinal data, OH is associated with increased
risk of major adverse cerebrocardiovascular events,
although results have not always been consistent
(43,47,48). Nonetheless, a recent meta-analysis of
prospective observational studies conﬁrmed that the
presence of OH was independently associated with
increased risk of all-cause death, incident coronary
heart disease, heart failure, and stroke (49). Unex-
pectedly, post-hoc subgroup analysis documented a
stronger association between OH and mortality in the
population <65 years of age, whereas such associa-
tion barely attained full statistical signiﬁcance in the
older subgroup (49). Similar discrepancies were also
observed in the ARIC (Atherosclerosis Risk in Com-
munities) study (50,51) and in the Cardiovascular
Health Study (52), in which the relative risk of stroke
predicted by OH decreased with advancing age. Pro-
spective data of the Swedish Malmö Preventive Proj-
ect showed a 2-fold higher risk of death in individualswith OH <42 years of age, strongly supporting a
causal relationship between OH and increased all-
cause mortality. An appreciation of the plausibility
of a pathophysiological link between the OH status
and negative outcomes, such as death and cere-
brocardiovascular events, requires several consider-
ations. Higher diurnal BP variability and supine
(nocturnal) hypertension, both present in OH, may
provoke intermittent bouts of increased afterload,
leading to permanent end-organ damage, such as left
ventricular hypertrophy and decreased renal func-
tion, thereby paving the way to left ventricular dia-
stolic dysfunction, increased risk of congestive heart
failure, and myocardial ischemia. Furthermore,
altered autonomic tone in patients with sleep apnea
(53) and hypertension (54) is known to be associated
with the occurrence of atrial ﬁbrillation (55,56), which
is itself a well-known risk factor for heart failure (57)
and cardioembolic stroke (58). Fedorowski et al. (59)
observed that, independent of conventional risk fac-
tors, the long-term incidence of atrial ﬁbrillation was
signiﬁcantly higher among individuals with hyper-
tension and OH, further strengthening the link be-
tween autonomic dysfunction and cardiovascular
morbidity. Impaired orthostatic homeostasis is
responsible for the activation of neuroendocrine
compensatory mechanisms, which may themselves
trigger the activation of other biological effectors
(e.g., platelets or the coagulation cascade), poten-
tially promoting the occurrence of cardiovascular or
cerebrovascular events. Corroborating this hypo-
thesis, hyperactivation of the endothelin system
has been observed in patients diagnosed with syn-
cope due to OH (60). Thus, physiological vasocon-
strictors, such as endothelin 1 and vasopressin,
which play an important role in adaptive mechanisms
during prolonged orthostatic stress, may promote
atherothrombotic events in susceptible individuals,
when chronically upregulated (61). However, current
knowledge does not allow us to draw any ﬁrm
conclusion as to whether OH is a marker of a generally
increased risk of death, an intermediate variable in
the causal pathway of cardiovascular risk factors, a
simple measure of disease severity, or an indepen-
dently acting mechanism. Thus, assessment of OH
in prospective epidemiological studies should be
encouraged. Moreover, future randomized trials in
chronic cardiovascular diseases, such as hyperten-
sion, ischemic heart disease, and heart failure, should
explore how prevalent OH inﬂuences study out-
comes, and whether bedtime intake of antihyperten-
sive drugs, aimed at restoring the nighttime dipping
pattern (62,63), can improve prognosis in patients
with the supine hypertension–OH syndrome (64).
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854DIAGNOSIS. OH is diagnosed on the basis of a simple
principle: to demonstrate a signiﬁcant persistent BP
decrease during orthostasis, either by the bedside
active-standing test or using a more sophisticated
head-up tilting test. The latter test is, however, not
always available and usually warrants interpretation
by a well-trained expert. The tests are usually per-
formed when the clinical scenario is suggestive of OH,
such as in the presence of characteristic postural
symptoms, unexplained syncope, or fall injury.
However, population-based epidemiological studies
have shown that OH is common in asymptomatic in-
dividuals (45,65) and may be accidentally found
during screening or routine clinical investigation
(66–69). Taking into account that OH prevalence is
strongly age dependent and up to one-third of pa-
tients >70 years of age may have it (66), we propose
that the bedside orthostatic test be routinely per-
formed in this age group, whereas patients <70 years
of age should probably undergo the orthostatic test
only if clinical signs suggestive of OH are present
(Figure 4). Apart from the orthostatic BP test, the
initial assessment of patients with suspected OH may
be complemented by standard cardiac and neurolog-
ical tests, according to past medical history; results of
the physical examination; and an electrocardiogram
(ECG). An expert in cardiovascular dysautonomia
should be responsible for the next stage in OH eval-
uation, having mandatory access to the head-up tilt
test and other autonomic tests, as well as to pro-
longed BP and ECG monitoring (Figure 4). However,
lack of real experts, both in numbers and local
accessibility, has always been an important limitation
in the implementation of such schemes. Tradition-
ally, specialists in either cardiology or neurology have
been involved in OH diagnostics at an advanced level.
Although the former are primarily oriented toward
the cardiovascular consequences of OH, such as syn-
cope, hypotension versus hypertension, and unex-
plained falls in older patients (23,40,70), the latter
predominantly focus upon the structural and func-
tional changes in the autonomic nervous system,
including cardiac autonomic imaging and neuroen-
docrine tests (28,29,71). Nevertheless, establishing a
higher number of centers with a trained and
adequately equipped professional staff would be an
important step toward optimal management of all
patients with OH. When properly diagnosed, patients
with OH may need referral to other specialists
(Figure 4), especially if the investigating unit lacks
competence in speciﬁc areas such as neurodegener-
ative diseases, dementia, endocrinology, cardiac
arrhythmias, or concomitant structural heart disease.
In summary, symptomatic patients (class II to IV)(Central Illustration) should undergo a more compre-
hensive investigation led by an expert in cardiovas-
cular dysautonomia, using at least the head-up tilting
test and 24-h ambulatory BP monitoring.
TREATMENT. The pivotal management of patients
with OH starts with an evaluation of the severity and
frequency of symptoms. Several useful grading tools
are available (71). We present a modiﬁed symptom
classiﬁcation along with treatment recommenda-
tions. As shown in the Central Illustration, the preva-
lence of OH functional classes (I to IV) is inversely
related to its severity, thus making asymptomatic OH
the most prevalent form of this disorder.
Pat ient educat ion . Patient education is central to
effective treatment of OH (Table 1). It is crucial that
patients understand the basics of postural physiology
and mechanisms of orthostatic intolerance, as well as
aggravating factors; learn how to avoid conditions
that potentially trigger symptoms and syncope; and
be instructed in how to prevent BP decreases using
physical countermeasures (72,73). When a patient is
tested with continuous noninvasive BP monitoring, it
is practical to perform a brief training session after
the test to instruct the patient on how muscle tension
and squatting can counteract BP decrease. Another
important aspect of patient education, concomitant
with a head-up tilting test, is proper recognition of
warning signs in relation to hemodynamic changes.
The efﬁcacy of countermeasures in a critical situation
depends on timely implementation, before irrevers-
ible circulatory collapse or vasovagal reﬂex activation
occurs (Figure 3).
Elast i c s tock ings and abdomina l b ind ing . When
the symptoms of orthostatic intolerance are very
pronounced (class III to IV) (Figure 4) and patient
education plus pharmacological treatment does not
lead to substantial improvement, and especially if the
decrease in SBP to <90 mm Hg occurs shortly after
standing and/or when signs of venous pooling are
present, elastic stockings and abdominal binding may
be helpful (Table 1) (74). Limb and abdomen
compression improves orthostatic tolerance in up to
40% of symptomatic patients. The recommended
compression pressure is 30 to 50 mm Hg for leg
compression and 20 to 30 mm Hg for the abdomen.
However, leg compression alone is not as effective as
compression of the abdomen because the venous
compartment of the lower limbs is smaller than that
of the splanchnic region (75,76); therefore, “the
higher, the better” principle should be applied. The
main disadvantage of this method is that compression
garments are inconvenient to put on and wear,
particularly for older and disabled patients and dur-
ing the summer season. However, the hemodynamic
FIGURE 4 Proposed Algorithm for the Diagnosis and Management of OH
When should we suspect orthostatic hypotension?
• Unexplained syncope/fall
• Typical symptoms (dizziness, lightheadedness, chronic fatigue, confusion, gait disorders, neck pain, vision disturbance)
• Patient’s history (age, neurodegenerative disease, diabetes, renal failure, amyloidosis, heart disease, hypertension,
autoimmune disease)
• Current pharmacological treatment (vasodilators, diuretics, alpha- and beta-blockers, tricyclic antidepressants)
Initial assessment (ED, hospital, and outpatient clinic)
• Physical examination
• Laboratory assessment (Hb, electrolytes, glucose, creatinine, TSH)
• Bedside BP supine/standing test (after 1-3-5 min)
• Cardiac assessment (ECG, telemetry or Holter-ECG, echocardiography, exercise-ECG, angiography if indicated,
i.e., history or signs of cardiac disease)
• Neurological assessment (neurological status, and brain imaging if indicated, i.e., history of head trauma and/or
neurological symptoms)
Please see Central Illustration for grading of symptoms and Table 1 for therapeutic options.
+
OH confirmed 9
Pharmacological/compression therapy (Class III-IV) Æ
ÆNonpharmacological methods + drug modification (Class I-II)     
Advanced cardiac and autonomic assessment (investigation unit led by experts) 
• Head-up tilt test with continuous BP monitoring plus active standing test, carotid sinus massage, and Valsalva test
(if positive, indicative of neurogenic OH); neuroendocrine assessment (supine and standing epinephrine/norepinephrine;
other biomarkers such as renin, endothelin-1, vasopressin, natriuretic peptides can be considered)
• 24-h-ambulatory BP monitoring (BP variability pattern? Nondipping? Reversed dipping? Diurnal hypotension
periods? Overtreatment? White-coat syndrome?)
• Long-term ECG monitoring if indicated (Cardiac arrhythmia? Chronotropic insufficiency?)
• Cardiac sympathetic neuroimaging (PET or MIBG, optional, if available)
Specialist consultation/referrals (if indicated)
• Cardiologist (OH with concurrent cardiac arrhythmia, structural heart disease, and/or severe hypertension)
• Neurologist (neurogenic OH and/or concurrent neurodegenerative disease such as Parkinson's disease, pure
autonomic failure, or multiple system atrophy)
• Geriatrician (older patient with special needs and comorbidities, fall tendency, cognitive impairment, dementia)
• Endocrinologist (patients with suspected or confirmed endocrine disorders such as electrolyte abnormalities,
hypothyroidism, or adrenal diseases) 
• Otolaryngologist  ("dizziness" with preserved normal hemodynamic parameters or typical vertigo)
ECG ¼ electrocardiography; ED ¼ emergency department; Hb ¼ hemoglobin; MIBG ¼ meta-iodobenzylguanidine; OH ¼ orthostatic
hypotension; PET ¼ positron emission tomography; TSH ¼ thyroid-stimulating hormone; other abbreviations as in Figure 3.
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CENTRAL ILLUSTRATION The Orthostatic Hypotension Pyramid
Daily, 
persistent, 
severe symptoms
Syncope is frequent
Frequent symptoms in normal conditions 
Regular symptoms in extreme conditions* 
Marked limitation of daily living activities
Syncope may occur; coping strategies reduce frequency
Sporadic symptoms in normal conditions (monthly to >1/week)
Irregular symptoms in extreme conditions*
Mild to moderate limitation of daily living activities
Syncope may be the first symptom of OH, and may reoccur in extreme conditions*
Mostly asymptomatic
Occasional symptoms and rare events (<1/yr)  such as presyncope, syncope, and/or unexplained falls 
Confirmed by diagnostic tests
III
II
I
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  s
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  s
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Prevalence of disease
4 Functional Classes Of Orthostatic Hypotension (OH)
Ricci, F. et al. J Am Coll Cardiol. 2015; 66(7):848–60.
Four classes of patients with orthostatic hypotension (OH) according to symptom severity. The prevalence of OH is progressively lower with
increasing symptoms. The overall prevalence of orthostatic hypotension in the middle-aged population is estimated to be 6% to 10%, but may
rise higher than 20% in those >75 years of age. The proportion of patients with class III to IV (i.e., with pronounced symptoms of orthostatic
intolerance) is approximately 1:10 in the overall population of patients with OH. Pharmacological treatment is necessary in class IV, is
recommended in class III, can be considered in class II, and is generally not recommended in class I patients (see also Figure 4). Illustration
inspired by a table in Low and Singer (71), with original changes. *Prolonged orthostatic stress, post-prandial, dehydration (e.g., post-exercise,
reduced ﬂuid intake, diarrhea, fever), morning hours after waking, excessive heat, shower use, initiation/intensiﬁcation of antihypertensive
treatment, and alcohol drinking.
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856effects exerted by compression garments are imme-
diate and easily recognized by the patient, and the
method can be applied only when needed (i.e., when
a prolonged orthostatic challenge is expected or
planned).
Pharmacolog ica l t reatment . Although nonphar-
macological measures are effective, most patients
with class III to IV orthostatic intolerance, experi-
encing severe, persistent, or very frequent symp-
toms, often immediately upon standing, require
pharmacological treatment with antihypotensive
drugs (Table 1). The efﬁcacy of such pharmacologicaltherapy has been repeatedly questioned, and very
few substances, including droxidopa and midodrine,
have shown positive results in randomized trials
(77,78), whereas small observational series have
demonstrated some effects of midodrine additive to
compression treatment (79,80). At present, droxidopa
and midodrine are preferred and administered during
the daytime to avoid nocturnal (supine) hypertension
because both substances have favorable half-lives of
approximately 3 h.
Droxidopa has been shown to improve orthostatic
tolerance in patients with neurogenic OH, having an
TABLE 1 Therapeutic Options in Symptomatic OH
Therapeutic modality Comments
Nonpharmacological treatment
Education of patient
 Acceptance and understanding of orthostatic intolerance
 Avoidance of immobilization, prolonged diurnal recumbence,
and physical deconditioning
 Gradual rising from supine and sitting positions, especially in
the morning, after meals, and after urination/defecation
 Small and frequent, rather than large, meals
 Avoidance of prolonged standing and high environmental
temperature and humidity (volume depletion)
 Physical countermaneuvers (e.g., leg crossing, muscle
tensing, squatting) during standing and prodromal symptoms
This therapeutic modality is crucial and often underestimated but is rarely
sufﬁcient in pronounced orthostatic intolerance (class III–IV). Patients and
their families should understand the basics of orthostatic physiology and the
importance of nonpharmacological methods. Training with
countermaneuvers and beat-to-beat monitoring of BP is recommended to
increase patient compliance. Educational materials such as instructional ﬁlms
may be helpful.
Head elevation 10–30 during sleep Reduction of nocturia, volume depletion, and supine hypertension.
Increased salt and ﬂuid intake, including peroral water bolus, if
needed
Volume expansion. Daily dietary intake of up to 10 g of sodium per day or salt
tablets (e.g., 1 g 3 times per day) and ﬂuid intake of at least 1.5 liters per day
is recommended. A careful dosage regimen in heart and kidney failure should
be followed.
Elastic stockings/abdominal binding Reduction of peripheral pooling in the lower limbs and splanchnic region.
Especially recommended for elderly patients.
Pharmacological treatments
Midodrine (2.5–10 mg 2 or 3 times per day) Direct alpha1-adrenoreceptor agonist. One of the few pharmacological agents
positively tested in placebo-controlled studies, but its efﬁcacy has often
been questioned.
Droxidopa (100–600 mg 3 times per day) Norepinephrine precursor. Has been widely used off-label in severe OH. Recently
approved by the FDA.
Pyridostigmine (30-60 mg 2 or 3 times per day) Acetylcholinesterase inhibitor. Generally recommended for neurogenic OH only.
BP increases marginally. Efﬁcacy questioned.
Fludrocortisone (0.05–0.3 mg daily) Mineralocorticoid. Volume expander. Increases sodium reabsorption and
enhances sensitivity of alpha-adrenoreceptors. May worsen supine
hypertension and hypokalemia.
Ephedrine/pseudoephedrine (25/30–50/60 mg 3 times per day) Direct and indirect alpha1-adrenoreceptor agonist. Efﬁcacy controversial.
Desmopressin (nasal spray, 5–40 mg daily; oral formulation,
100–800 mg daily)
Vasopressin analogue. Volume expander. Increases water reabsorption and
reduces nocturia. Efﬁcacy uncertain.
Avoidance of antihypertensive drugs: nitrates, long-acting calcium
channel blockers, and diuretics
Vasodilation and volume depletion. May worsen symptoms of orthostatic
intolerance.
Withdrawal, dosage reduction, or bedtime administration of
antihypertensive drugs (short-acting preferred)
Reversed BP dipping is common in OH. Assessment of 24-h BP proﬁle is
recommended to tailor antihypertensive therapy.
Devices
Pacemakers/CRT The role of pacemakers/CRT in OH is limited. However, if chronotropic
insufﬁciency and/or left ventricle failure worsen OH symptoms, especially in
elderly patients, device therapy may be considered.
BP ¼ blood pressure; CRT ¼ cardiac resynchronization therapy; FDA ¼ U.S. Food and Drug Administration; OH ¼ orthostatic hypotension.
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857impact on both symptoms upon daily activities and
standing SBP (increase by approximately 10 mm Hg)
(77). However, its long-term efﬁcacy is debatable.
Droxidopa treatment is usually initiated at a dosage of
100 mg 3 times per day (upon waking in the morning,
at midday, and in the late afternoon, at least 3 h prior
to bedtime; e.g., at 7 AM, 1 PM, and 7 PM) and should be
titrated until symptom reduction occurs in increments
of 100 mg per 3 to 7 days to a maximum dose of 600 mg
3 times per day. Typical adverse effects include
headache, dizziness, nausea, and aggravated hyper-
tension and may occur in 5% to 10% of patients. If
persistent, a dose reduction may be tested because
adverse effects are often dose dependent.
Midodrine has demonstrated a low to moderate
level of efﬁcacy in OH, according to a recent meta-
analysis (78). The drug has a positive impact onorthostatic intolerance (observed in approximately
50% of treated patients) and has no serious adverse
effects. On average, an increase in standing SBP of
10 to 15 mm Hg 1 h after drug administration has
been observed. Nevertheless, some uncomfortable
reactions (occurring in approximately 10% to 15% of
patients), such as dysuria or piloerection (“goose
bumps”) can be expected. Midodrine should be
administered according to the same schedule as
droxidopa, with a starting dose of 5 mg 3 times per day
and a recommended dose of 10 mg 3 times per day.
Vasoactive treatment may be complemented by a
volume expander, preferably ﬂudrocortisone (81),
due to its positive effect on alpha-adrenergic receptor
sensitivity. The usual starting dose is 0.1 mg once
daily and should not exceed 0.3 mg. Typical adverse
effects to observe in patients with OH are generalized
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858or localized edema, including pulmonary edema and
ascites, as well as aggravated hypertension and
hypokalemia. Thus, the use of ﬂudrocortisone in pa-
tients with heart failure, kidney failure, or hyper-
tension is contraindicated.
Another important aspect of pharmacological
therapy in OH is related to cardiovascular comorbid-
ities. Because several drugs used for treatment of
ischemic heart disease, heart failure, cardiac ar-
rhythmias, and hypertension may have a negative
impact on postural homeostasis, tailored therapy is
needed to avoid worsening of orthostatic symptoms
(Table 1). In general, 24-h ambulatory BP monitoring
should be performed ﬁrst, and nighttime adminis-
tration of short-acting antihypertensive drugs is
preferred, even if the patient is treated for ischemic
heart disease or heart failure. Drug classes to be
avoided are presented in Table 1.
In choosing a speciﬁc drug, a peak effect time
between 2 and 6 h and a half-life no longer than 12 h
are important. Recommended classes are angiotensin-
converting enzyme inhibitors (e.g., enalapril, ram-
ipril, benazepril, or moexipril), angiotensin-receptor
blockers (e.g., candesartan, losartan, valsartan, or
eprosartan), and dihydropyridine calcium-channel
blockers (e.g., felodipine, isradipine, or nifedipine)
given once daily at least 3 h before bedtime. Daytime
hypertensive episodes are of somewhat lesser
importance (62), whereas sleep-time hypertension
should be treated if BP is consistently higher than
160/90 mm Hg (82) in uncomplicated cases (i.e.,
symptomatic OH without concomitant target-organ
damage) and preferably lower than 140/90 mm Hg
in patients with a history of cerebrocardiovascular
disease, diabetes, or renal failure (63). A reverse
dipping pattern in combination with OH is particularly
detrimental and indicates a more than doubled risk ofincident cardiovascular disease (46). Consequently,
both the absolute reduction of nighttime BP and
restoration of normal sleep-time dipping are crucial
and can be easily monitored using repeated 24-h
ambulatory BP monitoring and patient diaries.
Furthermore, a reappraisal of the use of beta-blockers
is warranted because these patients, especially those
>70 years of age, often show signs of chronotropic
incompetence (83). Additional tests (Holter ECG and
exercise ECG testing) are recommended for decision-
making. However, in the most severe cases, discon-
tinuation of antihypertensive treatment may be the
only solution if the patient remains symptomatic
despite treatment modiﬁcation.CONCLUSIONS
OH is a frequent condition in the general population,
with a prevalence close to 6%, and the frequency
increases with advancing age and comorbidities.
Management of symptomatic OH consists of both
nonpharmacological and pharmacological methods,
but they are often unsatisfactory. Future studies
should focus on elucidating mechanisms involved in
neurodegenerative and non-neurodegenerative OH,
test new and more effective therapies, and assess the
impact of strategies aimed to prevent or treat OH on
cardiovascular diseases.
ACKNOWLEDGMENT The authors thank Lena Lyons
for the original artwork in Figure 1.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Raffaele De Caterina, Institute of Cardiology,
“G. d’Annunzio” University—Chieti, c/o Ospedale
SS. Annunziata—Via dei Vestini, 66013, Chieti, Italy.
E-mail: rdecater@unich.it.RE F E RENCE S1. Goldstein DS, Robertson D, Esler M, et al. Dys-
autonomias: clinical disorders of the autonomic
nervous system. Ann Intern Med 2002;137:
753–63.
2. Sutton R. Clinical classiﬁcation of syncope. Prog
Cardiovasc Dis 2013;55:339–44.
3. Fedorowski A, Melander O. Syndromes of
orthostatic intolerance: a hidden danger. J Intern
Med 2013;273:322–35.
4. Chopra S, Baby C, Jacob JJ. Neuro-endocrine
regulation of blood pressure. Indian J Endocrinol
Metab 2011;15 Suppl 4:S281–8.
5. Zanutto BS, Valentinuzzi ME, Segura ET. Neural
set point for the control of arterial pressure: role
of the nucleus tractus solitarius. Biomed Eng On-
line 2010;9:4.6. Dampney RA, Coleman MJ, Fontes MA, et al.
Central mechanisms underlying short- and long-
term regulation of the cardiovascular system.
Clin Exp Pharmacol Physiol 2002;29:261–8.
7. Janig W, McLachlan EM. Specialized functional
pathways are the building blocks of the auto-
nomic nervous system. J Auton Nerv Syst 1992;
41:3–13.
8. Goodman HM. Basic Medical Endocrinology. 3rd
edition. London: Academic Press, 2003.
9. Patel KP, Zhang K. Neurohumoral activation in
heart failure: role of paraventricular nucleus. Clin
Exp Pharmacol Physiol 1996;23:722–6.
10. Kramer JM, Plowey ED, Beatty JA, et al. Hy-
pothalamus, hypertension, and exercise. Brain Res
Bull 2000;53:77–85.11. Wadei HM, Textor SC. The role of the kidney in
regulating arterial blood pressure. Nat Rev Neph-
rol 2012;8:602–9.
12. Rhaleb NE, Yang XP, Carretero OA. The
kallikrein-kinin system as a regulator of cardio-
vascular and renal function. Compr Physiol 2011;1:
971–93.
13. Thompson WO, Thompson PK, Dailey ME. The
effect of posture upon the composition and vol-
ume of the blood in man. J Clin Invest 1928;5:
573–604.
14. Grubb BP, Karas B. Clinical disorders of the
autonomic nervous system associated with
orthostatic intolerance: an overview of classiﬁca-
tion, clinical evaluation, and management. Pacing
Clin Electrophysiol 1999;22:798–810.
J A C C V O L . 6 6 , N O . 7 , 2 0 1 5 Ricci et al.
A U G U S T 1 8 , 2 0 1 5 : 8 4 8 – 6 0 Orthostatic Hypotension
85915. Hainsworth R. Vascular capacitance: its control
and importance. Rev Physiol Biochem Pharmacol
1986;105:101–73.
16. Robertson D, Biaggioni I, Burnstock G, editors.
Primer on the Autonomic Nervous System. 3rd
edition. London: Academic Press, 2012.
17. Khurana I. Textbook of Human Physiology for
Dental Students. 2nd edition. New Dehli: Elsevier,
2013.
18. Kanjwal K, George A, Figueredo VM, et al.
Orthostatic hypotension: deﬁnition, diagnosis and
management. J Cardiovasc Med (Hagerstown)
2015;16:75–81.
19. Streeten DHP. Orthostatic Disorders of the
Circulation: Mechanisms, Manifestations, and
Treatment. New York: Plenum Publishing, 1987.
20. Harms MP, Wesseling KH, Pott F, et al.
Continuous stroke volume monitoring by model-
ling ﬂow from non-invasive measurement of
arterial pressure in humans under orthostatic
stress. Clin Sci (Lond) 1999;97:291–301.
21. Van Lieshout JJ, Wieling W, Karemaker JM,
et al. Syncope, cerebral perfusion, and oxygena-
tion. J Appl Physiol (1985) 2003;94:833–48.
22. Lambert E, Lambert GW. Sympathetic
dysfunction in vasovagal syncope and the postural
orthostatic tachycardia syndrome. Front Physiol
2014;5:280.
23. Task Force for the Diagnosis and Management
of Syncope, European Society of Cardiology (ESC),
European Heart Rhythm Association (EHRA); Heart
Failure Association (HFA); Heart Rhythm Society
(HRS); Moya A, Sutton R, et al. Guidelines for the
diagnosis and management of syncope (version
2009). Eur Heart J 2009;30:2631–71.
24. Freeman R, Wieling W, Axelrod FB, et al.
Consensus statement on the deﬁnition of ortho-
static hypotension, neurally mediated syncope and
the postural tachycardia syndrome. Clin Auton Res
2011;21:69–72.
25. Grubb BP. Clinical practice. neurocardiogenic
syncope. N Engl J Med 2005;352:1004–10.
26. Grubb BP, Kanjwal Y, Kosinski DJ. The postural
tachycardia syndrome: a concise guide to diag-
nosis and management. J Cardiovasc Electro-
physiol 2006;17:108–12.
27. Grubb BP. Neurocardiogenic syncope and
related disorders of orthostatic intolerance. Cir-
culation 2005;111:2997–3006.
28. Robertson D. The pathophysiology and diag-
nosis of orthostatic hypotension. Clin Auton Res
2008;18 Suppl 1:2–7.
29. Goldstein DS, Sharabi Y. Neurogenic ortho-
static hypotension: a pathophysiological
approach. Circulation 2009;119:139–46.
30. Trahair LG, Horowitz M, Jones KL. Post-
prandial hypotension: a systematic review. J Am
Med Dir Assoc 2014;15:394–409.
31. Li H, Kem DC, Reim S, et al. Agonistic auto-
antibodies as vasodilators in orthostatic hypoten-
sion: a new mechanism. Hypertension 2012;59:
402–8.
32. Goldstein DS, Tack C. Noninvasive detection of
sympathetic neurocirculatory failure. Clin Auton
Res 2000;10:285–91.33. Verheyden B, Gisolf J, Beckers F, et al. Impact
of age on the vasovagal response provoked by
sublingual nitroglycerine in routine tilt testing.
Clin Sci (Lond) 2007;113:329–37.
34. Wieling W, Krediet CT, van Dijk N, et al. Initial
orthostatic hypotension: review of a forgotten
condition. Clin Sci (Lond) 2007;112:157–65.
35. Gupta V, Lipsitz LA. Orthostatic hypotension in
the elderly: diagnosis and treatment. Am J Med
2007;120:841–7.
36. Fedorowski A, Engstrom G, Hedblad B, et al.
Orthostatic hypotension predicts incidence of
heart failure: the Malmö Preventive Project. Am J
Hypertens 2010;23:1209–15.
37. Strogatz DS, Keenan NL, Barnett EM, et al.
Correlates of postural hypotension in a community
sample of elderly blacks and whites. J Am Geriatr
Soc 1991;39:562–6.
38. Shin C, Abbott RD, Lee H, et al. Prevalence and
correlates of orthostatic hypotension in middle-
aged men and women in Korea: the Korean
Health and Genome Study. J Hum Hypertens
2004;18:717–23.
39. Krolewski AS, Warram JH, Cupples A, et al.
Hypertension, orthostatic hypotension and the
microvascular complications of diabetes. J Chronic
Dis 1985;38:319–26.
40. Fedorowski A, Burri P, Melander O. Ortho-
static hypotension in genetically related hyper-
tensive and normotensive individuals. J Hypertens
2009;27:976–82.
41. Räihä I, Luutonen S, Piha J, et al. Prevalence,
predisposing factors, and prognostic importance
of postural hypotension. Arch Intern Med 1995;
155:930–5.
42. Sasaki O, Nakahama H, Nakamura S, et al.
Orthostatic hypotension at the introductory phase
of haemodialysis predicts all-cause mortality.
Nephrol Dial Transplant 2005;20:377–81.
43. Masaki KH, Schatz IJ, Burchﬁel CM, et al.
Orthostatic hypotension predicts mortality in
elderly men: the Honolulu Heart Program. Circu-
lation 1998;98:2290–5.
44. Verwoert GC, Mattace-Raso FU, Hofman A,
et al. Orthostatic hypotension and risk of cardio-
vascular disease in elderly people: the Rotterdam
study. J Am Geriatr Soc 2008;56:1816–20.
45. Eigenbrodt ML, Rose KM, Couper DJ, et al.
Orthostatic hypotension as a risk factor for stroke:
the Atherosclerosis Risk in Communities (ARIC)
study, 1987-1996. Stroke 2000;31:2307–13.
46. Fagard RH, De Cort P. Orthostatic hypotension
is a more robust predictor of cardiovascular events
than nighttime reverse dipping in elderly. Hyper-
tension 2010;56:56–61.
47. Weiss A, Beloosesky Y, Kornowski R, et al.
Inﬂuence of orthostatic hypotension on mortality
among patients discharged from an acute geriatric
ward. J Gen Intern Med 2006;21:602–6.
48. Hossain M, Ooi WL, Lipsitz LA. Intra-individual
postural blood pressure variability and stroke in
elderly nursing home residents. J Clin Epidemiol
2001;54:488–94.
49. Ricci F, Fedorowski A, Radico F, et al. Car-
diovascular morbidity and mortality related toorthostatic hypotension: a meta-analysis of pro-
spective observational studies. Eur Heart J 2015;
36:1609–17.
50. Rosamond WD, Folsom AR, Chambless LE,
et al. Stroke incidence and survival among middle-
aged adults: 9-year follow-up of the Atheroscle-
rosis Risk in Communities (ARIC) cohort. Stroke
1999;30:736–43.
51. Rose KM, Eigenbrodt ML, Biga RL, et al. Ortho-
static hypotension predicts mortality in middle-aged
adults: the Atherosclerosis Risk in Communities
(ARIC) study. Circulation 2006;114:630–6.
52. Manolio TA, Kronmal RA, Burke GL, et al.
Short-term predictors of incident stroke in older
adults. The Cardiovascular Health Study. Stroke
1996;27:1479–86.
53. Gami AS, Hodge DO, Herges RM, et al.
Obstructive sleep apnea, obesity, and the risk of
incident atrial ﬁbrillation. J Am Coll Cardiol 2007;
49:565–71.
54. Okin PM, Wachtell K, Kjeldsen SE, et al. Inci-
dence of atrial ﬁbrillation in relation to changing
heart rate over time in hypertensive patients: the
LIFE study. Circ Arrhythm Electrophysiol 2008;1:
337–43.
55. Hou Y, Scherlag BJ, Lin J, et al. Ganglionated
plexi modulate extrinsic cardiac autonomic nerve
input: effects on sinus rate, atrioventricular con-
duction, refractoriness, and inducibility of atrial
ﬁbrillation. J Am Coll Cardiol 2007;50:61–8.
56. Nakagawa H, Scherlag BJ, Patterson E, et al.
Pathophysiologic basis of autonomic ganglionated
plexus ablation in patients with atrial ﬁbrillation.
Heart Rhythm 2009;6:S26–34.
57. ACTIVE I Investigators. Irbesartan in patients
with atrial ﬁbrillation. N Engl J Med 2011;364:
928–38.
58. Ricci F, Renda G, De Caterina R. Antith-
rombotic therapy in atrial ﬁbrillation: state of the
art and perspectives [in Italian]. G Ital Cardiol
(Rome) 2013;14:21–34.
59. Fedorowski A, Hedblad B, Engström G, et al.
Orthostatic hypotension and long-term incidence
of atrial ﬁbrillation: the Malmö Preventive Project.
J Intern Med 2010;268:383–9.
60. Fedorowski A, Burri P, Struck J, et al. Novel
cardiovascular biomarkers in unexplained syncopal
attacks: the SYSTEMA cohort. J Intern Med 2013;
273:359–67.
61. Berger R, Pacher R. The role of the endothelin
system in myocardial infarction—new therapeutic
targets? Eur Heart J 2003;24:294–6.
62. Hermida RC, Ayala DE, Mojón A, et al.
Decreasing sleep-time blood pressure deter-
mined by ambulatory monitoring reduces car-
diovascular risk. J Am Coll Cardiol 2011;58:
1165–73.
63. Hermida RC, Ayala DE, Mojón A, et al. Sleep-
time ambulatory blood pressure as a novel thera-
peutic target for cardiovascular risk reduction.
J Hum Hypertens 2014;28:567–74.
64. Romero-Ortuno R, O’Connell MD,
Finucane C, et al. Insights into the clinical
management of the syndrome of supine hyper-
tension—orthostatic hypotension (SH-OH): the
Ricci et al. J A C C V O L . 6 6 , N O . 7 , 2 0 1 5
Orthostatic Hypotension A U G U S T 1 8 , 2 0 1 5 : 8 4 8 – 6 0
860Irish Longitudinal Study on Ageing (TILDA). BMC
Geriatr 2013;13:73.
65. Rutan GH, Hermanson B, Bild DE, et al.
Orthostatic hypotension in older adults. The
Cardiovascular Health Study. CHS Collabora-
tive Research Group. Hypertension 1992;19:
508–19.
66. Low PA. Prevalence of orthostatic hypoten-
sion. Clin Auton Res 2008;18 Suppl 1:8–13.
67. Gangavati A, Hajjar I, Quach L, et al.
Hypertension, orthostatic hypotension, and the
risk of falls in a community-dwelling elderly
population: the Maintenance of Balance, Inde-
pendent Living, Intellect, and Zest in the
Elderly of Boston study. J Am Geriatr Soc 2011;
59:383–9.
68. Shibao C, Grijalva CG, Raj SR, et al. Orthostatic
hypotension-related hospitalizations in the United
States. Am J Med 2007;120:975–80.
69. Weiss A, Grossman E, Beloosesky Y, et al.
Orthostatic hypotension in acute geriatric ward: is
it a consistent ﬁnding? Arch Intern Med 2002;162:
2369–74.
70. Ungar A, Morrione A, Rafanelli M, et al. The
management of syncope in older adults. Minerva
Med 2009;100:247–58.71. Low PA, Singer W. Management of neurogenic
orthostatic hypotension: an update. Lancet Neurol
2008;7:451–8.
72. Wieling W, van Dijk N, Thijs RD, et al. Physical
countermeasures to increase orthostatic toler-
ance. J Intern Med 2015;277:69–82.
73. Benditt DG, Nguyen JT. Syncope: therapeutic
approaches. J Am Coll Cardiol 2009;53:1741–51.
74. Podoleanu C, Maggi R, Brignole M, et al. Lower
limb and abdominal compression bandages pre-
vent progressive orthostatic hypotension in elderly
persons: a randomized single-blind controlled
study. J Am Coll Cardiol 2006;48:1425–32.
75. Figueroa JJ, Basford JR, Low PA. Preventing
and treating orthostatic hypotension: as easy as
A, B, C. Cleve Clin J Med 2010;77:298–306.
76. Protheroe CL, Dikareva A, Menon C, et al. Are
compression stockings an effective treatment for
orthostatic presyncope? PloS One 2011;6:e28193.
77. Keating GM. Droxidopa: a review of its use in
symptomatic neurogenic orthostatic hypotension.
Drugs 2015;75:197–206.
78. Izcovich A, González Malla C, Manzotti M,
et al. Midodrine for orthostatic hypotension and
recurrent reﬂex syncope: a systematic review.
Neurology 2014;83:1170–7.79. Hurst GC, Somerville KT, Alloway RR, et al.
Preliminary experience with midodrine in kidney/
pancreas transplant patients with orthostatic hy-
potension. Clin Transplant 2000;14:42–7.
80. Hohler AD, Amariei DE, Katz DI, et al.
Treating orthostatic hypotension in patients with
Parkinson’s disease and atypical Parkinsonism
improves function. J Parkinsons Dis 2012;2:
235–40.
81. Maule S, Papotti G, Naso D, et al. Ortho-
static hypotension: evaluation and treatment.
Cardiovasc Hematol Disord Drug Targets 2007;7:
63–70.
82. Fedorowski A. Aiming too high or too low?
Searching for the appropriate therapeutic thresh-
olds in hypertension is not over yet. Evid Based
Med 2015;20:27.
83. Sahul ZH, Trusty JM, Erickson M, et al. Pacing
does not improve hypotension in patients with
severe orthostatic hypotension—a prospective
randomized cross-over pilot study. Clin Auton Res
2004;14:255–8.
KEY WORDS autonomic dysfunction,
cardiovascular events, orthostatic
hypotension, postural homeostasis
